• Home
• Forums
• Contact
• About
• Privacy Policy and Legal Stuff.

Subscribe

FDA approves Vyvanse

A new ADHD drug by Shire, that is enginered to be harder to abuse than it’s sister drug Adderall XR or other amphetamine based drugs.

Via CNN:

Vyvanse works by gradually releasing its active ingredient, d-amphetamine, after the drug has been swallowed and comes into contact with enzymes in the digestive tract.
Unless it’s swallowed, Vyvanse remains inactive. Shire believes that will curtail its potential for abuse by users who snort or inject crushed pills.
Despite those measures, the Drug Enforcement Administration has proposed making Vyvanse a Schedule II drug, a class that includes cocaine, methadone, methamphetamine and other drugs with a high potential for abuse.

Did Shire actually expect this new drug to be anything but a C-II?

Comments